UNSPSC 51293006: Cotriptyline

This classification denotes an antidepressant agent with the molecular formula C20H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KQJ4QI511C, chemically known as 1-(dimethylamino)-3-(10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-ylidene)-2-propanone but generally known as cotriptyline, which bears US NIH Compound Identifier 71935. European Medicines Agency schedules Cotriptyline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06812MIG.

UNSPSC 51293006 Cotriptyline is a Commodity code nominally identifying a specific tricyclic antidepressant pharmaceutical, but recent state and local procurement activity under this code bears little connection to that product. The three most recent opportunities posted under the code—a Seminole County naloxone and drug deactivation systems bid, a Texas HHS direct-to-manufacturer prescription program RFI, and a Minnesota cooperative purchasing RFP for generic multi-source pharmaceuticals and OTC products—indicate that the code is being used as a catch-all pharmaceutical or pharmaceutical-adjacent services category rather than for cotriptyline procurement specifically. State and local governments are using this code to solicit pharmaceutical supply agreements, pharmacy benefit management initiatives, and controlled-substance-related health equipment, not the narrow product the code name suggests. Issuing bodies include county health departments (Seminole County, Florida), state health commissions (Texas HHS), and multistate cooperative purchasing alliances (MMCAP, Minnesota Department of Administration), signaling that pharmacy and controlled-substance procurement spans multiple jurisdiction types and administrative structures.

Recent activity appears concentrated in Florida and Texas, with multistate cooperative purchasing also active through Minnesota. The Seminole County IFB (IFB60459723LAS), posted June 30, 2026 with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with the contract potentially FEMA-funded and subject to federal compliance requirements. The Texas HHS Commission issued an RFI (HHS0017013) on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program to improve fulfillment efficiency and cost management outside traditional pharmacy benefit manager channels. The Minnesota MMCAP RFP (S1070000015802), due March 26, 2026, established multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with vendor awards effective July 1, 2026 and evaluation weighted primarily on price competitiveness (75 percent) and fixed pricing (10 percent). The mismatch between the code name and actual procurement suggests business development professionals should verify issuing-body classification and scope carefully when pursuing opportunities tagged under this code.